文献速递核素与放射性配体治疗放射性药物与辐射防护

载γ-生育三烯酚脂质体减轻放射性药物造血副作用

γ-Tocotrienol-Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs.
PubMed 文献 · J Nucl Med · 2020-08-21

该研究开发了载γ-生育三烯酚的脂质体(GT3-Nano),在小鼠中评估其对亚致死和致死全身照射及153Sm-EDTMP治疗所致骨髓辐射损伤的保护作用。结果显示GT3-Nano可促进造血快速恢复、提高致死剂量照射后的生存率,并减少153Sm-EDTMP的骨髓抑制。

要点

  • GT3-Nano在4 Gy全身照射前后24小时给药均可促进小鼠造血完全恢复。
  • GT3-Nano在9 Gy致死性照射下呈剂量依赖性辐射防护,50 mg/kg时生存率达90%。
  • GT3-Nano可促进153Sm-EDTMP治疗小鼠的造血成分快速恢复。

核心结论

  • GT3-Nano能有效减轻小鼠亚致死和致死性全身照射的骨髓抑制效应,并促进153Sm-EDTMP内照射治疗后的造血恢复。

研究设计与样本

  • 临床前小鼠研究:将GT3被动载入脂质体制成GT3-Nano,用64Cu-GT3-Nano和3H-GT3-Nano研究体内生物分布,并在137Cs全身照射(4 Gy、9 Gy)或单次高剂量153Sm-EDTMP后评估辐射防护效果。

主要发现

  • 24小时骨髓摄取和滞留(每克组织注射剂量百分比)为64Cu-GT3-Nano 6.98 ± 2.34、3H-GT3-Nano 7.44 ± 2.52。
  • 4 Gy全身照射前或后24小时给予GT3-Nano可促进快速且完全的造血恢复,而对照组恢复停滞在60%。
  • GT3-Nano在9 Gy致死性全身照射下呈剂量依赖性辐射防护,50 mg/kg时生存率达90%。
  • 流式细胞术显示GT3-Nano处理小鼠骨髓中祖细胞MPP2和CMP上调;免疫组化显示GT3-Nano蓄积于CD105阳性窦状上皮细胞。

临床怎么用

  • GT3-Nano有望作为辐射防护剂,减轻靶向放射性核素治疗期间的骨髓辐射损伤,促进造血恢复。

局限性

  • 研究仅在小鼠中进行,尚未在人体验证其辐射防护效果和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the successful development and increased use of targeted radionuclide therapy for treating cancer comes the increased risk of radiation injury to bone marrow-both direct suppression and stochastic effects, leading to neoplasia. Herein, we report a novel radioprotector drug, a liposomal formulation of γ-tocotrienol (GT3), or GT3-Nano for short, to mitigate bone marrow radiation damage during targeted radionuclide therapy. Methods: GT3 was loaded into liposomes using passive loading. 64Cu-GT3-Nano and 3H-GT3-Nano were synthesized to study the in vivo biodistribution profile of the liposome and GT3 individually. The radioprotection efficacy of GT3-Nano was assessed after acute 137Cs whole-body irradiation at a sublethal (4 Gy), a lethal (9 Gy), or a single high-dose administration of 153Sm-ethylenediamine-N,N,N',N'-tetrakis(methylene phosphonic acid) (EDTMP). Flow cytometry and fluorescence microscopy were used to analyze hematopoietic cell population dynamics and the cellular site of GT3-Nano localization in the spleen and bone marrow, respectively. Results: Bone marrow uptake and retention (percentage injected dose per gram of tissue) at 24 h was 6.98 ± 2.34 for 64Cu-GT3-Nano and 7.44 ± 2.52 for 3H-GT3-Nano. GT3-Nano administered 24 h before or after 4 Gy of total-body irradiation (TBI) promoted rapid and complete hematopoietic recovery, whereas recovery of controls stalled at 60%. GT3-Nano demonstrated dose-dependent radioprotection, achieving 90% survival at 50 mg/kg against lethal 9-Gy TBI. Flow cytometry of the bone marrow indicated that progenitor bone marrow cells MPP2 and CMP were upregulated in GT3-Nano-treated mice. Immunohistochemistry showed that GT3-Nano accumulates in CD105-positive sinusoid epithelial cells. Conclusion: GT3-Nano is highly effective in mitigating the marrow-suppressive effects of sublethal and lethal TBI in mice. GT3-Nano can facilitate rapid recovery of hematopoietic components in mice treated with the endoradiotherapeutic agent 153Sm-EDTMP.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lee SG, Kalidindi TM, Lou H, et al. γ-Tocotrienol-Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs. J Nucl Med. 2020. PMID: 32826318. doi:10.2967/jnumed.120.244681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。